TOKYO and BOSTON, Sept. 28, 2026 /Kyodo JBN/ --
SOLA Biosciences Japan GKSOLA Biosciences Japan Receives AMED Grant to Advance SOL-257, Innovative Gene Therapy Aiming to Restore TDP-43 Function for ALS Patients SOLA Biosciences Japan GK ("SOLA Japan"), the wholly owned Japanese subsidiary of Boston-based SOLA Biosciences Inc. (together, "SOLA"), announced that it has been awarded a grant of approximately 6 billion yen over five years by the Japan Agency for Medical Research and Development ("AMED") under the Strengthening Program for Pharmaceutical Startup Ecosystem. The award was announced…READ FULL ARTICLE
